% | $
Quotes you view appear here for quick access.

Anthera Pharmaceuticals, Inc. Message Board

  • afrezza_fda_approval afrezza_fda_approval Sep 27, 2012 10:50 AM Flag

    B-mod a Superior Choice for Doctors over Benlysta

    This is a recent exerpt from Life Science Advisors:

    "In this follow-up note, we discuss Anthera Pharmaceuticals’ (NASDAQ: ANTH) recently released Phase 2b PEARL-SC secondary endpoint results, which demonstrated 29% (p=0.002) and 31% (p 10) that showed a 13.8% treatment, Anthera recently reported strong results for the SRI-6, SRI-7, and SRI-8 measures."

    As you can see, the street is pretty much clueless as far as b-mod's enormous overall potential is concerned. This is basically an "under-the-radar" stock. People, IMO, will eventually begin piling in and a huge run-up should ensue.The stock was at 1.6 when this report was published, and the authors are adament that the valuation - even at 1.6 - is grossly undervalued. IMO, this goes well into the teens and possibly in the 20's at some point following approval.

    Indubitably, B-mod will be a superior choice for doctors over Benlysta; primarily, because it will target a pre-defined SLE population. This attribute will help deliver excellent results on a more consistent basis. In short, it will immensely help the patients that it’s prescribed for -- rather than guessing and risking reputational damage. SLE is a very difficult disease to treat, because the symptoms vary greatly from patient to patient. Narrowing this prognostic gap is paramount in effectively treating the disease. This has been one of Benlysta’s biggest challenges and it seems that ANTH has found the perfect solution.

    ANTHs risk/reward is absolutely remarkable right here. I have been buying hand-over-fist at these 1 and sub-1 levels.

    Disclosure: I am Long and these are my own opinions based solely on my research.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
2.67-0.34(-11.30%)Feb 5 4:00 PMEST